Literature DB >> 21195928

Sequence of cellular events in pancreatic islets leading to impaired insulin secretion in chronic kidney disease.

Shaul G Massry1.   

Abstract

OBJECTIVES: In chronic renal failure (CRF), a multitude of metabolic derangements occur in the pancreatic islets, resulting in impaired glucose-induced insulin secretion. These abnormalities include a rise in the basal level of cytosolic calcium ([Ca(2+)]i) in the islets, a decrease in their basal and stimulated adenosine triphosphate (ATP) and adenosine diphosphate (ADP) content, a reduction in the V(max) of Ca(2+) ATPase and Na(+)-K(+) ATPase, and an impaired glucose-induced calcium signal. The sequence of events that leads to these derangements and to the impairment in insulin secretion during the evolution of CRF has not been defined. This study examined this particular issue by measuring the metabolic profiles of pancreatic islets weekly during the evolution of CRF over a period of 6 weeks.
RESULTS: The results showed that serum levels of parathyroid hormone (PTH) begin to rise during the first week of CRF. The V(max) of Ca(2+) ATPase and Na(+)-K(+) ATPase increased during weeks 1 to 3 of CRF but decreased to low levels thereafter. At week 3 of CRF, the basal level of [Ca(2+)]i began to rise, whereas basal and stimulated ATP and ADP content started to fall. Glucose-induced calcium signal, Δ[Ca(2+)]i, and insulin secretion became abnormally low between weeks 3 and 6 of CRF.
CONCLUSION: The data obtained allow for the inference of the following formulation: as serum levels of PTH begin to rise, calcium entry into islets is augmented, which in turn will stimulate the activity of Ca(2+) ATPase and the Na(+)-Ca(2+) exchanger, and therefore, calcium extrusion out of the islets is increased. Thus, [Ca(2+)]i remains normal during the first 2 weeks of CRF. Activation of the Na(+)-Ca(2+) exchanger may result in accumulation of sodium in the islets, an event that would activate the Na(+)-K(+) ATPase. Because calcium entry is further augmented by the progressive rise in serum PTH levels, mitochondrial oxidation and ATP production would be reduced, resulting in lower ATP content. This fall in ATP causes a reduction in the V(max) of Ca(2+) ATPase and Na(+)-K(+) ATPase, and therefore calcium extrusion out of the islets is reduced; consequently, [Ca(2+)]i rises. With the decrease in ATP content and the rise in [Ca(2+)]i, glucose-induced insulin secretion is impaired because of alterations in the closure of ATP-dependent potassium channels and reduction in the glucose-induced calcium signal (Δ[Ca(2+)])i.
Copyright © 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21195928     DOI: 10.1053/j.jrn.2010.11.001

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  4 in total

Review 1.  Current therapeutic approaches in the management of hyperglycemia in chronic renal disease.

Authors:  Vishnu Garla; Licy Yanes-Cardozo; Lillian F Lien
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

2.  Mechanism of insulin resistance in a rat model of kidney disease and the risk of developing type 2 diabetes.

Authors:  François Dion; Christopher Dumayne; Nathalie Henley; Stéphanie Beauchemin; Edward B Arias; François A Leblond; Sylvie Lesage; Stéphane Lefrançois; Gregory D Cartee; Vincent Pichette
Journal:  PLoS One       Date:  2017-05-01       Impact factor: 3.240

Review 3.  Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.

Authors:  Jianzhen Ye; Guangrui Deng; Feng Gao
Journal:  Drug Des Devel Ther       Date:  2018-04-19       Impact factor: 4.162

4.  Improving Glucose Homeostasis after Parathyroidectomy for Normocalcemic Primary Hyperparathyroidism with Co-Existing Prediabetes.

Authors:  Spyridon Karras; Cedric Annweiler; Dimitris Kiortsis; Ioannis Koutelidakis; Kalliopi Kotsa
Journal:  Nutrients       Date:  2020-11-16       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.